MedWatch

Genmab-chief: ”We have a potential blockbuster in Arzerra”

New, positive data from a phase III study with leukaemia drug Arzerra pleases Genmab’s CEO, Jan Van de Winkel. But he reclines from commenting on the analyst consensus which puts sales just shy of USD 300 million by 2017.

Foto: Genmab/PR

There are still high hopes for sales growth for Arzerra in coming years, and consensus is at DKK 1.7 billion (USD 299 million), according to major German bank, Deutsche Bank. That is triple the current level, as Arzerra – which is licensed to drug giant GlaxoSmithKline - sold for DKK 552 million (USD 97 million) in 2012. DKK 111 million (USD 19.5 million) of that was passed on to Genmab through a royalty agreement.

Sales of the drug have been rapidly increasing in recent years, although is very narrow, as it is aimed exclusively at seriously ill patients, often over the age of 65.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Eli Lilly får forlomme til fedmehåb hos FDA

Med en fast track status får medicinalselskabet Eli Lilly sænket behandlingstiden for sin registreringsansøgning hos FDA af lægemiddelhåbet Tirzepatid til omtrent seks måneder fra de normale ca. 10 måneder.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier